Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Acute exacerbations of chronic bronchitis - What role for the new fluoroquinolones?
Autore:
Obaji, A; Sethi, S;
Indirizzi:
Dept Vet Affairs Western New York Healthcare Syst, VA Med Res 151, Buffalo, NY 14215 USA Dept Vet Affairs Western New York Healthcare Syst Buffalo NY USA 14215 SA SUNY Buffalo, Div Pulm & Crit Care Med, Buffalo, NY 14260 USA SUNY Buffalo Buffalo NY USA 14260 & Crit Care Med, Buffalo, NY 14260 USA
Titolo Testata:
DRUGS & AGING
fascicolo: 1, volume: 18, anno: 2001,
pagine: 1 - 11
SICI:
1170-229X(2001)18:1<1:AEOCB->2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE BACTERIAL EXACERBATIONS; RESPIRATORY-TRACT INFECTIONS; OBSTRUCTIVE PULMONARY-DISEASE; ANTIMICROBIAL SURVEILLANCE PROGRAM; QT-INTERVAL PROLONGATION; IN-VITRO ACTIVITY; DOUBLE-BLIND; STREPTOCOCCUS-PNEUMONIAE; CEFUROXIME AXETIL; HAEMOPHILUS-INFLUENZAE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
50
Recensione:
Indirizzi per estratti:
Indirizzo: Sethi, S Dept Vet Affairs Western New York Healthcare Syst, VA Med Res 151, 3495 Bailey Ave, Buffalo, NY 14215 USA Dept Vet Affairs Western New York Healthcare Syst 3495 Bailey Ave Buffalo NY USA 14215
Citazione:
A. Obaji e S. Sethi, "Acute exacerbations of chronic bronchitis - What role for the new fluoroquinolones?", DRUG AGING, 18(1), 2001, pp. 1-11

Abstract

Acute exacerbations of chronic bronchitis (AECB) are a major cause of morbidity and mortality. Bacterial pathogens ore implicated in about half the episodes of AECB. Empirical antibacterials have a significant benefit in AECB; however. several recent developments have considerably complicated antibacterial choice for this condition. New fluoroquinolone antibacterials introduced in the last decade are theoretically well suited for the treatment of AECB, as the in vitro antimicrobial spectrum of these drugs includes all the major pathogens involved. The pharmacokinetic and pharmacodynamic properties of the new fluoroquinolones are superior to many other antibacterialsused to treat AECB. In trials, clinical success with the new fluoroquinolones was equivalent and bacteriological success was occasionally superior tononfluoroquinolone comparators. However, these clinical trials did not assess several potentially important end-points for which the theoretical superiority of the fluoroquinolones may translate into differences in outcome. Rare but serious adverse effects with some of the new fluoroquinolones haveshaken the confidence of prescribing physicians in this class of drugs. Emergence of the resistance of Streptococcus pneumoniae to fluoroquinolones has raised concerns about indiscriminate and widespread use of the new agents for trivial infections. Patients: with AECB are a heterogeneous population who should be stratified in order to appropriately choose empirical antibacterial therapy. Highly efficacious antibacterial therapy, such as the newfluoroquinolones, is appropriate as a first-line choice for patients who have risk factors for a poor outcome or are in intensive care units. Such selected use of the new fluoroquinolones balances individual benefit with societal concerns of the use of these agents for AECB.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 20:06:46